Nidanilimab, CAS 2171061-85-9

Product Description: Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy./[2]Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.

CAS Number: 2171061-85-9

Molecular Weight: N/A

Compound Purity: 99.90

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99379-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99379-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK